Literature DB >> 33652709

Pitfalls in the Serological Diagnosis of Primary Human Cytomegalovirus Infection in Pregnancy Due to Different Kinetics of IgM Clearance and IgG Avidity Index Maturation.

Antonella Sarasini1, Alessia Arossa2, Maurizio Zavattoni1, Chiara Fornara1, Daniele Lilleri1, Arsenio Spinillo2, Fausto Baldanti1,3, Milena Furione1.   

Abstract

Primary infection occurs when seronegative women are infected by human cytomegalovirus (HCMV). Diagnosis of primary infection is based on the following: antibody seroconversion, presence of IgM and low IgG avidity index (AI), and presence of DNAemia. The kinetics of HCMV-specific IgM antibody and maturation of AI might be very rapid or long-lasting during primary infection, which makes serological diagnosis insidious. The aims of this study were as follows: (i) to report atypical kinetics of HCMV-specific IgM antibody and AI early after onset of primary HCMV infection in a population of pregnant women, and (ii) to assess the frequency of such results. Altogether, 1309 sequential serum samples collected from 465 pregnant women with primary HCMV infection were included in the study. As a general rule, using the LIAISON®CMVIgMII and LIAISON®CMVIgGAvidityII assays, virus-specific IgM antibody levels decreased, while IgG AI increased over time during the first three months after infection onset. However, early clearance of IgM antibody and/or early IgG AI maturation occurred in 46/426 (10.7%) women. In more details, 20/426 (4.7%) and 26/418 (6.2%) women had undetectable IgM antibody or high IgG AI, respectively, when tested within 1-3 months after well-defined infection onset. Twenty sera from as many women with high IgG AI by the LIAISON assay were further tested for IgG AI by VIDAS®CMVIgGAvidityII and Mikrogen recomLineCMVIgG Avidity assays. Comparable results were obtained with VIDAS, whereas 14/20 sera gave low AI with the Mikrogen assay. In conclusion, about 11% of pregnant women undergoing a primary HCMV infection showed misleading serological results. Additional and appropriate testing might help in reducing the risk of missing HCMV primary infection in pregnancy. Furthermore, preconceptional testing should be strongly recommended.

Entities:  

Keywords:  DNAemia; HCMV primary infection; IgG antibody; IgG avidity; IgM antibody; dating of infection onset; pregnancy

Year:  2021        PMID: 33652709      PMCID: PMC7996894          DOI: 10.3390/diagnostics11030396

Source DB:  PubMed          Journal:  Diagnostics (Basel)        ISSN: 2075-4418


  24 in total

1.  Role of prenatal diagnosis and counseling in the management of 735 pregnancies complicated by primary human cytomegalovirus infection: a 20-year experience.

Authors:  Maria Grazia Revello; Elisa Fabbri; Milena Furione; Maurizio Zavattoni; Daniele Lilleri; Beatrice Tassis; Aida Quarenghi; Chiara Cena; Alessia Arossa; Laura Montanari; Vanina Rognoni; Arsenio Spinillo; Giuseppe Gerna
Journal:  J Clin Virol       Date:  2011-02-01       Impact factor: 3.168

2.  Potential impact of different cytomegalovirus (CMV) IgM assays on an algorithm requiring IgM reactivity as a criterion for measuring CMV IgG avidity.

Authors:  Harry E Prince; Mary Lapé-Nixon; Andrew Brenner; Nancy Pitstick; Marc Roger Couturier
Journal:  Clin Vaccine Immunol       Date:  2014-03-26

3.  Perinatal Outcomes of Non-Primary Maternal Cytomegalovirus Infection: A 15-Year Experience.

Authors:  Giuliana Simonazzi; Alessandra Curti; Francesca Cervi; Liliana Gabrielli; Margherita Contoli; Maria Grazia Capretti; Nicola Rizzo; Brunella Guerra; Antonio Farina; Tiziana Lazzarotto
Journal:  Fetal Diagn Ther       Date:  2017-07-12       Impact factor: 2.587

4.  Cytomegalovirus DNAemia in pregnant women.

Authors:  Maria Grazia Revello; Milena Furione; Vanina Rognoni; Alessia Arossa; Giuseppe Gerna
Journal:  J Clin Virol       Date:  2014-10-18       Impact factor: 3.168

5.  Maternal immunity and prevention of congenital cytomegalovirus infection.

Authors:  Karen B Fowler; Sergio Stagno; Robert F Pass
Journal:  JAMA       Date:  2003-02-26       Impact factor: 56.272

6.  Prevention of child-to-mother transmission of cytomegalovirus by changing behaviors: a randomized controlled trial.

Authors:  S P Adler; J W Finney; A M Manganello; A M Best
Journal:  Pediatr Infect Dis J       Date:  1996-03       Impact factor: 2.129

7.  Slow increase in IgG avidity correlates with prevention of human cytomegalovirus transmission to the fetus.

Authors:  Milena Furione; Vanina Rognoni; Antonella Sarasini; Maurizio Zavattoni; Daniele Lilleri; Giuseppe Gerna; Maria Grazia Revello
Journal:  J Med Virol       Date:  2013-07-25       Impact factor: 2.327

8.  Neutralizing and ELISA IgG antibodies to human cytomegalovirus glycoprotein complexes may help date the onset of primary infection in pregnancy.

Authors:  D Lilleri; G Gerna; M Furione; M Zavattoni; A Spinillo
Journal:  J Clin Virol       Date:  2016-05-17       Impact factor: 3.168

9.  Diagnosis and outcome of preconceptional and periconceptional primary human cytomegalovirus infections.

Authors:  Maria Grazia Revello; Maurizio Zavattoni; Milena Furione; Daniele Lilleri; Giovanna Gorini; Giuseppe Gerna
Journal:  J Infect Dis       Date:  2002-07-19       Impact factor: 5.226

10.  Washing our hands of the congenital cytomegalovirus disease epidemic.

Authors:  Michael J Cannon; Katherine Finn Davis
Journal:  BMC Public Health       Date:  2005-06-20       Impact factor: 3.295

View more
  2 in total

1.  Human cytomegalovirus (HCMV) long-term shedding and HCMV-specific immune response in pregnant women with primary HCMV infection.

Authors:  C Fornara; F Zavaglio; M Furione; A Sarasini; P d'Angelo; A Arossa; A Spinillo; D Lilleri; F Baldanti
Journal:  Med Microbiol Immunol       Date:  2022-08-12       Impact factor: 4.148

Review 2.  Pitfalls in the Serological Evaluation of Maternal Cytomegalovirus Infection as a Potential Cause of Fetal and Neonatal Involvements: A Narrative Literature Review.

Authors:  Shigeo Iijima
Journal:  J Clin Med       Date:  2022-08-26       Impact factor: 4.964

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.